June 3, 2020 / 11:08 AM / a month ago

BRIEF-Bristol-Myers - New Data Reinforce Durable Clinical Responses Of Orencia In Early Rheumatoid Arthritis

June 3 (Reuters) - Bristol-Myers Squibb Co:

* NEW DATA REINFORCE IMPROVED AND DURABLE CLINICAL RESPONSES OF ORENCIA IN MODERATE-TO-SEVERE EARLY RHEUMATOID ARTHRITIS PATIENTS WITH AUTOANTIBODIES LINKED TO MORE SEVERE DISEASE

* BRISTOL-MYERS SQUIBB CO - SEROPOSITIVE PATIENTS SWITCHING FROM ADALIMUMAB TO ORENCIA SHOWED TREND TOWARD HIGHER EFFICACY AT WEEK 48

* BRISTOL-MYERS - AMONG 76 SEROPOSITIVE RA PATIENTS WHO ENTERED OPEN-LABEL SWITCH PERIOD OVERALL SAFETY PROFILE OF ORENCIA WAS CONSISTENT WITH PRIOR STUDIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below